Remove 2014 Remove Leads Remove Safety
article thumbnail

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

pharmaphorum

A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.

article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018.

Pharma 255
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

Out of the seven biologics approved to treat moderate to severe CD in adults, only the anti-TNFαs, Remicade (infliximab), and Humira (adalimumab), have been approved for paediatric patients, with Humira receiving the most recent approval in 2014.

Medical 59
article thumbnail

Pfizer’s haemophilia B gene therapy meets phase 3 primary endpoint

pharmaphorum

during the lead-in pre-treatment period of at least six months. Key secondary endpoints demonstrated a 78% reduction in treated ABR and a 92% reduction in annualised infusion rate, and SPK-9001 was generally well-tolerated, its safety profile consistent with phase 1 and phase 2 results.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. This could lead to significant research waste. 2014 Jan;32(1):40-51. References Attwood D, Curley A, Keenan E, Murphy S. Mechoulam R.

Medical 98
article thumbnail

Targeted therapies for chronic lymphocytic leukaemia in an evolving treatment landscape

European Pharmaceutical Review

1 The cancer is a slow-growing but potentially life-threatening B-cell malignancy, in which increased activation of B-cell receptor signalling pathways leads to overgrowth of lymphocytes in bone marrow and other disease compartments. for all-comers; HR=0.52

Safety 52
article thumbnail

The U.S. health insurance market is undergoing a post-pandemic sea change

Clarivate

Insurance exchanges underwent their largest single-year enrollment growth since their inception in 2014, pushing exchange enrollment to yet another all-time high. This may also lead to gaps in care, reduced drug adherence, increased emergency room visits and a decline in chronic care management. The post The U.S.